Scarica l'app Stockscreener
457.03
1.08%
4.87
Dopo l'orario di chiusura:
450.00
-7.03
-1.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$452.16
Aprire:
$449.81
Volume 24 ore:
978.22K
Relative Volume:
0.60
Capitalizzazione di mercato:
$115.95B
Reddito:
$11.10B
Utile/perdita netta:
$-988.90M
Rapporto P/E:
-116.59
EPS:
-3.92
Flusso di cassa netto:
$-1.26B
1 W Prestazione:
+2.51%
1M Prestazione:
+2.60%
6M Prestazione:
+12.64%
1 anno Prestazione:
-3.54%
Intervallo 1D:
$448.00
$457.75
Intervallo di 1 settimana:
$439.23
$457.75
Portata 52W:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
10 Biotech Stocks Screaming a Buy - Insider Monkey
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives - Insider Monkey
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Price Target Slightly Reduced by R - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts - Nasdaq
Vertex Pharmaceuticals price target lowered to $420 from $423 at RBC Capital - TipRanks
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns - GuruFocus
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns | VRTX Stock News - GuruFocus
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating - MarketScreener
Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.
Aries Wealth Management Buys New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Everhart Financial Group Inc. Buys 553 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CCM Investment Advisers LLC Acquires 5,351 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Opinicus Capital Inc. Invests $397,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Ferguson Wellman Capital Management Inc. Takes $391,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by RMR Wealth Builders - MarketBeat
Integrated Advisors Network LLC Has $1.05 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Optas LLC Has $864,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Brighton Jones LLC Purchases 1,994 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Foster Victor Wealth Advisors LLC Sells 1,664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Massachusetts Wealth Management Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Yousif Capital Management LLC Sells 664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simplicity Wealth LLC Has $630,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Redhawk Wealth Advisors Inc. Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com
Compagnie Lombard Odier SCmA Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simon Quick Advisors LLC Has $1.42 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SG Americas Securities LLC Purchases 17,502 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Greenwood Capital Associates LLC Sells 6,572 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Stanley Laman Group Ltd. Buys New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UMB Bank n.a. Sells 1,666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Handelsbanken Fonder AB Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
Boston drug company laying off 125 employees in R.I. - Boston.com
Boston probes misconduct claims against city official - Axios
Portside Wealth Group LLC Has $1.43 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Presents New Data on the Benefits of ALYFTREK - Insider Monkey
Vertex Pharmaceuticals lays off 125 workers in RI - WPRI.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lifted by Wedmont Private Capital - MarketBeat
Boston drugmaker Vertex slashes Providence workforce, shrinks real estate following trial failure - The Business Journals
SeaCrest Wealth Management LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex to lay off 125 employees in R.I., consolidate offices - The Boston Globe
Vertex lays off 125 staffers, slims Rhode Island campus after ditching failed diabetes cell-device combo - Fierce Biotech
Vertex lays off 125 staffers after halting work on diabetes 'cells plus device' therapy - FirstWord Pharma
After axing diabetes asset, Vertex lays off 140 staff - PharmaLive
After Axing Diabetes Asset, Vertex Lays Off 140 Staff - BioSpace
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks? - MSN
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.40%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):